combined dyslipidemia after 3 months of treatment. Clinically relevant changes in other lipid parameters were also observed. These included reductions in total cholesterol (TC), triglycerides (TGs), ApoB and increases in HDL-C levels. Clinical and preclinical studies also show pitavastatin is taken up into the liver by multiple hepatic transporter mechanisms, and is minimally metabolized by cytochrome P450 (CYP); therefore, the risk of potential drug-drug interactions (DDIs) is reduced [18] [19] [20] [21] [22] .
Based on this Phase II evidence, initial pitavastatin therapy with 2 mg or 4 mg was expected to have an LDL-C-lowering effect similar to the most common doses of first-line statins used in Europe and North America. The purpose of this Phase III study was to demonstrate the equivalence of pitavastatin (2 and 4 mg) by assessment of noninferiority at equipotent doses, compared with the most commonly prescribed doses of atorvastatin (10 mg and 20 mg) in reducing LDL-C in patients with primary hypercholesterolemia or combined dyslipidemia.
Patients & methods n Study design
This was a multicenter, prospective, randomized, double-blind, double-dummy, controlled trial, which was carried out by investigators at 39 clinical sites in India, Denmark, Russia and Spain, from 4 October 2005 to 8 November 2006 . Subjects who qualified for the study were asked to follow a European Atherosclerosis Society (EAS) diet during a 6-8-week dietary lead-in period, to ensure adequate wash-out of prior therapy and establish stable baseline lipid values. This was followed by a 12-week treatment period (Figure 1) .
The primary objective of the study was to demonstrate the equivalence of pitavastatin compared with commonly used doses of atorvastatin in reducing LDL-C levels in patients with primary hypercholesterolemia or combined dyslipidemia. Secondary objectives included comparing pitavastatin with commonly used doses of atorvastatin for achievement of National Cholesterol Education Program Adult Treatment Panel (NCEP ATP) III goals and EAS LDL-C goals, changes in other lipid parameters and safety [23, 24] .
Equivalence was assessed by demonstrating the noninferiority of presumed equipotent doses of pitavastatin and atorvastatin. The noninferiority margin of 6% used in this study approximates the treatment difference in percent reduction in LDL-C levels that might be expected from doubling a statin dose. This margin is also well within the difference in LDL-C reduction observed between pitavastatin and placebo in previous studies [25, 26] . The treatment duration of 12 weeks was based on previously published trials in statins for hypercholesterolemia and combined dyslipidemia [27] [28] [29] . . The target-attainment criteria for this study were based on LDL-C-reduction goals set by the NCEP ATP III (risk-adjusted), and the EAS general treatment goal of LDL-C less than 115 mg/dl (3.0 mmol/l).
A total of 800 randomized patients were planned to be recruited and randomized 3:1 between the two pitavastatin doses and the two atorvastatin doses. Patients randomized to the two higher doses were treated with the lower doses for the first 4 weeks and then force-titrated to the higher doses for 8 weeks. Assuming a standard deviation of 12 for percent reduction from baseline LDL-C, a noninferiority limit of 6% for the treatment difference and a 1-tailed test at 2.5% significance level, this sample size would provide 99% power to reject the null hypothesis for this study -that the mean percent decrease from baseline LDL-C is at least 6% greater in the atorvastatin groups than in the pitavastatin groups.
This trial was designed and conducted in accordance with the Declaration of Helsinki (version amended in October, 2000), the CHMP guidelines and the ethical principles of Good Clinical Practice. Appropriate review boards approved the trial, and informed consent was obtained from all participants after the purpose and nature of the investigation had been explained to them. Statistical analyses were performed by the Biostatistics Department at PharmaNet Ltd, Buckinghamshire, UK.
n Patient population Subjects eligible for inclusion were men and nonpregnant, nonlactating women, aged 18 to 75 years, diagnosed with primary hypercholesterolemia or combined dyslipidemia. Any previously prescribed lipid-regulating drugs were discontinued at screening and all patients were asked to follow an approved EAS diet during a lead-in/ washout period of 6-8 weeks (8 weeks for those who had previously received lipid-regulating drugs and 6 weeks for those who had not). At each visit during the lead-in period, a 12-hour fasting blood sample was taken to determine qualifying lipid levels. Patients who were compliant with the diet, and had mean fasting LDL-C levels greater than or equal to 160 mg/dl (4.1 mmol/l) and less than or equal to 220 mg/dl (5.7 mmol/l), and TG levels of less than or equal to 400 mg/ dl (4.5 mmol/l) at the end of the lead-in period were eligible for randomization in the trial. All blood samples to assess efficacy and safety were assayed at a central laboratory (Global Central Laboratories PPD, Zaventem, Belgium). LDL-C was estimated using the Friedewald equation [30] .
The main exclusion criteria for the trial included previous contraindications or intolerance to statin therapy, homozygous familial hypercholesterolemia, familial hypoalphalipoproteinemia, conditions that might have caused secondary dyslipidemia, uncontrolled diabetes mellitus, pregnancy, conditions affecting absorption, distribution, metabolism or excretion of drugs, symptomatic heart failure (New York Heart Association classification III or IV), significant cardiovascular disease, impaired pancreatic function, liver enzyme levels greater than 1.5 times the upper limit of normal, impaired renal function, impaired urinary tract function, uncontrolled hypothyroidism, symptomatic cerebrovascular disease, left ventricular ejection fraction less than 0.25, uncontrolled hypertension, muscular or neuromuscular disease, neoplastic disease, treatment with other lipid-lowering drugs and treatment that would interact with the pharmacokinetics of statins. Women of child bearing potential were only allowed to participate if they were using a r eliable contraceptive method.
Patients who qualified for the trial were randomly assigned to one of four treatment groups: pitavastatin 2 mg/day, pitavastatin 4 mg/day (force-titrated from 2 mg/day), atorvastatin 10 mg/day or atorvastatin 20 mg/day (forcetitrated from 10 mg/day) (Figure 1 ). An interactive voice response system randomized all patients to one of the groups at visit 4 (week 0) in the ratios 3:3:1:1, respectively. Investigators, their staff, patients and the sponsor were then kept blinded to lipid results and treatment information until the database was locked. Commercially available atorvastatin tablets were overencapsulated and a matching placebo capsule was produced so that a double-blind, double-dummy design could be used to maintain the blind in this study. Suitable analytical testing was conducted to confirm that overencapsulation had no impact on the oral delivery of test materials. Target attainment was assessed against the NCEP LDL-C goal determined for each patient according to his/her risk category and the EAS LDL-C goal of less than 115 mg/dl (3.0 mmol/l).
The secondary efficacy variables were calculated as the percent change from baseline in TC, HDL-C, non-HDL-C, TG, ApoB, Apo-A1, C-reactive protein measured using a high-sensitivity assay (hs-CRP) and oxidized LDL; and the change in the TC:HDL-C, non-HDL-C:HDL-C, and ApoB:Apo-A1 ratios at the end of 12 weeks of treatment were also calculated. No noninferiority limit was set for secondary end points.
Safety variables focused on the incidence of AEs and changes from baseline in safety laboratory values, with particular emphasis on elevations of liver (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) and muscle Table 1 . demographic and other baseline characteristics (whole study population). 
Duration of current disease (years)
Mean (SD) 3.4 (3.9) 3.4 (4) 
Data & statistical analyses
Following the treatment period, the 821 subjects in this trial were divided into the following populations for analysis, defined as:
n Safety population: all randomized patients who received at least one dose of the study drug;
n The full analysis set (FAS): all randomized patients who received at least one dose of study drug and who had at least one on-treatment lipid assessment;
n The per-protocol (PP) population: all patients in the FAS, who had no major protocol violations, and who had an on-treatment lipid assessment at week 12 (visit 8).
The FAS population was the principal population used for the efficacy analyses and the PP population was used for confirmatory analysis of the efficacy end points.
In the FAS and PP populations, the primary efficacy variable (percent change in LDL-C from baseline to week 12) was assessed using analysis of covariance (ANCOVA), including terms for treatment, country and baseline as covariates. Two-sided 95% confidence intervals (CI) were constructed on the adjusted mean difference between the following treatment groups: atorvastatin 10 mg minus pitavastatin 2 mg and atorvastatin 20 mg minus pitavastatin 4 mg. Pitavastatin was considered equivalent to atorvastatin if the lower bound on the 95% CI was greater than -6% for all doses tested.
Safety assessments involved the monitoring and recording of all spontaneously reported AEs and serious AEs. Blood test results were analyzed to evaluate the number and proportion of patients with serum transaminases (AST and ALT) or CK values greater than one-, three-, five-and 10-times the upper limit of the reference range (ULRR). Patients with CK elevations greater than or equal to 5 × ULRR but less than 10 × ULRR were reviewed weekly until they returned to within the normal range or the abnormality was considered chronic (30 days after first observation).
Investigators carried out electrocardiogram evaluations and physical examinations on each patient at the beginning of the dietary lead-in period (visit 1/week -6/8) and the end of the study (visit 8/week 12) or upon early treatment discontinuation.
Results n Baseline characteristics
Patient characteristics and lipid levels in each of the four randomized pitavastatin and atorvastatin groups at baseline are summarized in Table 1 . The treatment groups were well matched in terms of age, vital statistics (height, weight and BMI) and disease diagnosis and duration. Approximately 79% of patients in each treatment group had primary hypercholesterolemia (78.4 to 79.1%) and most of the remainder had combined dyslipidemia. The groups were also well matched in diagnosis of hypertension and in baseline lipid values. Study subjects included slightly more women than men, and this balance was ref lected across the treatment groups. Approximately half of the patients were classified as high risk according to NCEP criteria and there was an n Primary efficacy analysis The reductions in LDL-C from baseline to end point for the lower-dose study groups (pitavastatin 2 mg vs atorvastatin 10 mg) were 37.9 and 37.8 %; respectively (Figure 2, Table 2) , with an adjusted mean difference of -0.15 (Table 2) .
For the higher-dose study groups (pitavastatin 4 mg vs atorvastatin 20 mg), the LDL-C reductions were 44.6 and 43.5%, respectively, with a mean difference of 0.96 (Figure 3 , Table 2 ). The lower 95% CI limits in the higher-dose and lower-dose comparisons were -2.32% and -3.42%, respectively -well clear of the noninferiority limit of -6% (Figure 4 ). These findings showed that the efficacy of pitavastatin in LDL-C reduction was equivalent to atorvastatin in the principal patient population at these dosage levels. The analysis in the PP population confirmed these study findings.
The results also showed no significant treatment by subgroup interactions. Subgroups included age, sex, race, BMI, risk category, baseline LDL-C, hypertension, diabetes and primary diagnosis (primary hypercholesterolemia or combined dyslipidemia).
n Secondary efficacy analysis Attainment of LDL-C target levels
As presented in Table 3 , using the NCEP criteria, the lower-dose comparison appeared to show an advantage for atorvastatin 10 mg over pitavastatin 2 mg (65.7% vs 56.8%), while the higherdose comparison showed an apparent advantage for pitavastatin 4 mg over atorvastatin 20 mg (77.9% vs 70.6%). Neither of these differences was statistically significant. The observed treatment differences were smaller for the EAS criteria.
n Other lipids As seen in Table 4 , reductions from baseline in TC, non-HDL-C, TC:HDL-C ratio, non-HDL-C:HDL-C ratio, ApoB, and ApoB:Apo-A1 ratio were very similar between the two lowerdose treatment groups and between the two higher-dose groups. The higher-dose groups showed consistently greater decreases than the lower-dose groups. The increases from baseline in HDL-C were slightly greater in the pitavastatin lower-dose and higher-dose study groups (4 and 5%) than the corresponding atorvastatin groups (3 and 2.5%). The reductions in TG were somewhat greater in the two atorvastatin groups (17.7 and 22.3%) than in the corresponding pitavastatin groups (14 and 19%) . None of the differences were statistically significant. Pitavastatin compared with atorvastatin in hypercholesterolemia| ReseaRch aRticle n Safety All treatments were well tolerated, as shown in Table 5 . Although patients were randomized 3:1 between pitavastatin and atorvastatin in each treatment group, the overall incidence of treatment-emergent AEs was similar in each comparison. Most AEs were mild to moderate in intensity and considered unrelated to study medications. Rates of treatment discontinuation due to AEs were minimal, and only occurred in the pitavastatin groups (2%). The most commonly reported treatment-related AE (TRAE) leading to withdrawal was myalgia: 0.9% (three patients) in the pitavastatin 2 mg group and 0.7% (two patients) in the pitavastatin 4 mg group (Table 6 ). The majority of TRAEs seen in this study were also mild or moderate in intensity, with the most frequently reported TRAE being nasopharyngitis (3.2% in pitavastatin 2 mg; 2.7% in pitavastatin 4 mg; 3.9% in atorvastatin 10 mg; 2.9% atorvastatin 20 mg). Shift tables of laboratory values from baseline to week 12 did not indicate any treatment-or dose-related trends. In particular, there were no discernible trends in AST, ALT or CK.
Discussion
In large clinical studies, considerable evidence shows that first-line statin therapy effectively achieves LDL-C target levels in a wide range of patients [31, 32] . In everyday life, effective maintenance of LDL-C targets is also important to reduce cholesterol risk on a long-term basis [33] [34] [35] . However, follow-up studies of established statins show that as many as six out of ten patients stop taking therapy during the first 6 months of treatment. Statin discontinuation and noncompliance may be due to a variety of factors, including high statin dosage, polypharmacy, lack of titration, intolerance and complicated treatment regimens [7, [33] [34] [35] [36] [37] [38] . Socioeconomic factors may also affect LDL-C target attainment and maintenance: women, the elderly and ethnic minorities are often undertreated for atherogenic problems [38] [39] [40] [41] . As such, there remains a need for an effective, well-tolerated statin that can provide a good balance of cardioprotective benefits and improved multiple lipid parameters over the long-term, using a lower dosage and a simple treatment regimen. Pitavastatin was launched in Japan in 2003, South Korea in 2005 and Thailand in 2008. Since then, it has been successfully used in these countries as a first-line statin therapy to treat primary hypercholesterolemia and combined dyslipidemia in a wide range of patients, including the elderly and those on concurrent medications [42] . Following the success of pitavastatin in the Far East, larger European Phase III trials were then carried out. Based on Phase II findings, the LDL-C lowering effect of pitavastatin at 2 mg and 4 mg was expected to compare well with the most commonly used doses of clinically established first-line statins in Europe, Canada and the USA.
This Phase III study set out to investigate this hypothesis by comparing the highest proposed doses of pitavastatin (2 and 4 mg) with the most commonly used doses of atorvastatin (10 and 20 mg). The atorvastatin 10 and 20 mg doses are also the recommended starting doses for patients with primary hypercholesterolemia Pitavastatin compared with atorvastatin in hypercholesterolemia| ReseaRch aRticle and combined dyslipidemia [43] . This trial was not designed to be a coronary heart disease study. Target attainment was assessed against the NCEP LDL-C goal determined for each patient according to their risk category and the EAS LDL-C goal of less than 115 mg/dl (3.0 mmol/l) [23, 24] . Atorvastatin is available at a range of doses up to 80 mg/day [43] and has end point studies to demonstrate the effect of LDL-C reduction on outcomes. Such studies have not been conducted with pitavastatin. The trial findings indicate that pitavastatin doses (2 and 4 mg) were equivalent to the most commonly prescribed doses of atorvastatin (10 mg and 20 mg) in the reduction of LDL-C in patients with primary hypercholesterolemia and combined dyslipidemia. Pitavastatin was as effective as atorvastatin at bringing patients -nearly half of whom were higher-risk -to the NCEP and EAS LDL-C targets in this study.
While results showed these specific statin doses were matched for LDL-C reduction, there were some interesting differences in secondary lipids. The adjusted mean differences (statistically nonsignificant) in HDL-C favored pitavastatin in both the higher and lower-dose comparisons. A dose-response with pitavastatin and a reverse dose-response with atorvastatin indicated that the HDL-C increase with pitavastatin 4 mg was double that of the HDL-C elevation with atorvastatin 20 mg. The reverse dose response with atorvastatin on HDL-C has previously been observed [44] .
The role of HDL-C is still being assessed in lipid-lowering therapy. A recent meta-analysis assessing 23 studies of cholesterol reduction by any means concluded that since HDL-C elevation and LDL-C reduction are statistically independent for moderate percentage changes, these could be considered additive [45] . Recent literature also reports the pro-atherogenic properties of low HDL-C concentrations in patients with diabetes or metabolic syndrome [46] .
In this study, pitavastatin appeared to be as effective as atorvastatin in reducing TG levels, although atorvastatin produced slightly greater reductions. Other lipid analyses in this study also showed no significant differences between pitavastatin and atorvastatin regarding changes in the following lipid parameters: TC, non-HDL-C, ApoB, Apo-A1, TC:HDL-C ratio, non-HDL-C:HDL-C ratio, and ApoB:Apo-A1 ratio and oxidized LDL. Other analyses also showed no apparent differences between pitavastatin and atorvastatin in treatment effects on hs-CRP.
Regarding safety and tolerability, the overall incidence of TRAEs was similar among all treatment groups, and the majority were mild to moderate in intensity and considered unrelated to study medications. In this trial, myalgia was the most common TRAE leading to withdrawal for 0.9% of patients in the pitavastatin 2 mg group and 0.7% of patients in the pitavastatin 4 mg group. The unbalanced randomization in the study population (300 patients in each pitavastatin group and 100 patients in each atorvastatin group) could account for the fact that no withdrawals due to AEs were observed in the atorvastatin groups [47] . In previous studies with atorvastatin, the rate of withdrawal due to AEs related to treatment has been approximately 2% compared with the 2% rate due to any adverse event, related or unrelated, seen with pitavastatin in this trial [48] .
Throughout the trial, 61% of patients were on concurrent medication for hypertension, but the study excluded patients taking medications that might interact with atorvastatin, and no significant DDIs were identified in patients taking either pitavastatin or atorvastatin. In fact, pitavastatin has a favorable metabolic profile as it is minimally metabolized by CYP isoenzymes and, in particular, has no interaction with CYP 3A4. In addition, pitavastatin is not a substrate for P-glycoprotein (P-gp). This metabolic profile suggests that pitavastatin has less risk of potential DDIs in unselected patients on concurrent therapy [18] [19] [20] [21] [22] . 
Conclusion
In patients with primary hypercholesterolemia and combined dyslipidemia in a range of cardiovascular risk categories (nearly half with high cardiovascular risk), pitavastatin doses of 2 mg/ day and 4 mg/day were as effective as atorvastatin doses of 10 mg/day and 20 mg/day in reducing LDL-C, TG, and TC, and i ncreasing HDL-C concentrations. The majority of patients reached treatment targets on the lower dose, and this percentage was increased at the higher doses of pitavastatin and atorvastatin. The safety and tolerability profiles with each statin were similar, with no indications of any dose-related AEs. Overall, this study suggests that in patients who are controlled with atorvastatin at doses of 10 or 20 mg per day, pitavastatin could be considered an effective, first-line alternative that provides a simple, low-dose treatment regimen for primary h ypercholesterolemia and combined dyslipidemia.
Future perspective
Patients at LDL-C treatment targets have a reduced risk of cardiovascular events but, as statin use becomes more widespread, there is an increasing need for broader protection from cardiovascular risk than that provided by LDL-C reduction alone, in a wider range of more complex-to-treat patients. Age, diabetes, ethnicity and add-on therapy for low HDL-C concentrations and other concurrent treatment should not preclude such patients from receiving effective, long-term statin therapy. A new statin that is appropriate as first-line therapy in a broad range of patients using a simple treatment regimen could have a valuable place in the future management of cardiovascular disease. 
